327 related articles for article (PubMed ID: 15205192)
1. Pharmacological background of EGFR targeting.
Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
[TBL] [Abstract][Full Text] [Related]
2. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Blackledge G; Averbuch S
Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
[TBL] [Abstract][Full Text] [Related]
5. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
Harari PM; Huang SM
Semin Radiat Oncol; 2001 Oct; 11(4):281-9. PubMed ID: 11677653
[TBL] [Abstract][Full Text] [Related]
6. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
Gainet M; Guardiola E; Dufresne A; Pivot X
Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.
Fischel JL; Formento P; Milano G
Br J Cancer; 2005 Mar; 92(6):1063-8. PubMed ID: 15756277
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
10. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
11. Why the epidermal growth factor receptor? The rationale for cancer therapy.
Baselga J
Oncologist; 2002; 7 Suppl 4():2-8. PubMed ID: 12202782
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
Ciardiello F; De Vita F
Prog Drug Res; 2005; 63():93-114. PubMed ID: 16265878
[No Abstract] [Full Text] [Related]
14. EGFR pathway in advanced non-small cell lung cancer.
Merlo V; Longo M; Novello S; Scagliotti GV
Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393
[TBL] [Abstract][Full Text] [Related]
15. Targeting the epidermal growth factor receptor.
El-Rayes BF; LoRusso PM
Br J Cancer; 2004 Aug; 91(3):418-24. PubMed ID: 15238978
[TBL] [Abstract][Full Text] [Related]
16. Growth factors and their receptors: new targets for prostate cancer therapy.
Barton J; Blackledge G; Wakeling A
Urology; 2001 Aug; 58(2 Suppl 1):114-22. PubMed ID: 11502465
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor inhibition in solid tumours.
Ganti AK; Potti A
Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
19. [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
Fartoux L; Desbois-Mouthon C; Poupon R; Rosmorduc O
Gastroenterol Clin Biol; 2006 Oct; 30(10):1133-5. PubMed ID: 17075466
[No Abstract] [Full Text] [Related]
20. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]